摘要
目的:观察养心氏联合常规西药治疗冠心病经皮冠状动脉介入(PCI)术后的临床疗效。方法:选取2017年4月至2018年12月青岛大学附属医院收治的冠心病PCI术后的患者84例作为研究对象,按照随机数字表法随机分为对照组和观察组,每组42例。对照组患者给予冠心病PCI术后常规西药治疗,观察组在常规治疗基础上加用养心氏片,疗程为8周。观察2组患者治疗前后心绞痛发作情况、心电图、血管内皮功能、炎性反应因子和血脂水平的变化,进行评估比较。结果:观察组心绞痛总有效率90.48%,显著高于对照组61.90%;观察组心电图总有效率92.70%,显著高于对照组57.14%;观察组的血管内皮功能、炎性反应因子和血脂水平变化与对照组比较,差异有统计学意义(P<0.05)。结论:冠心病PCI术后患者在常规西药治疗基础上加用养心氏片,可显著改善患者术后再发心绞痛症状,改善心电图异常,改善血管内皮功能和血脂异常,减轻炎性反应,疗效可靠。
Objective:To observe the clinical efficacy and hematologic changes of Yangxinshi Tablets combined with routine western medicine in the treatment of coronary heart disease after PCI.Methods:A total of 84 patients with coronary heart disease after PCI who were treated in the Affiliated Hospital of Qingdao University from April 2017 to December 2018 were selected and randomly divided into an observation group and a control group,with 42 patients in each group.The control group was treated with routine western medicine of coronary heart disease after PCI,while the observation group received Yangxinshi Tablets on the basis of routine treatment with the course of 8 weeks.The changes of angina symptoms,electrocardiogram,endothelial function,inflammatory factors and lipid levels of the 2 groups before and after treatment were recorded and evaluated.Results:The total effective rate of angina in the observation group was 90.48%,which was significantly higher than 61.90%of the control group.The total effective rate of ECG of the observation group was 92.70%,which was significantly higher than 57.14%of the control group.There were significant differences in the endothelial function,inflammatory factors and lipid levels between the observation group and the control group(P<0.05).Conclusion:Yangxinshi Tablets combined with routine western medicine can significantly improve the angina symptoms,ECG abnormity,endothelial function and lipid abnormality of coronary heart disease patients after PCI as well as restrain inflammation.The curative effect of Yangxinshi Tablets is reliable.
作者
王耀霞
李凤晓
于良健
马敏
苏治国
Wang Yaoxia;Li Fengxiao;Yu Liangjian;Ma Min;Su Zhiguo(Department of Pharmacy,the Affiliated Hospital of Qingdao University,Qingdao 266003,China)
出处
《世界中医药》
CAS
2019年第11期3024-3027,共4页
World Chinese Medicine
基金
青岛市海洋生物医药科技创新项目(2017-CXZX01-4-3)
作者简介
王耀霞(1981.04—),女,硕士研究生,主管药师,研究方向:神经药理学,E-mail:yaoxia99@163.com;通信作者:苏治国(1984.09—),男,硕士研究生,主管药师,研究方向:药剂学,E-mail:suzhiguo919@126.com。
